• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT IRELAND DIAGNOSTICS DIVISION ARCHITECT ANTI-HBS REAGENT KIT; TEST, HEPATITIS B (B CORE, BE ANTIGEN, BE ANTIBODY, B CORE IGM)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT IRELAND DIAGNOSTICS DIVISION ARCHITECT ANTI-HBS REAGENT KIT; TEST, HEPATITIS B (B CORE, BE ANTIGEN, BE ANTIBODY, B CORE IGM) Back to Search Results
Catalog Number 07C18-29
Device Problem High Test Results (2457)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 12/22/2023
Event Type  malfunction  
Manufacturer Narrative
An evaluation is in process.A follow-up report will be submitted when the evaluation is complete.All available patient information was included.Additional patient details are not available.This report is being filed on an international product, list number 07c18-29, that has a similar product distributed in the us, list number 01l82.
 
Event Description
The customer observed false reactive architect anti-hbs results for one patient.The customer suspects the results to be falsely reactive since it does not match results for the immunochromatography method.The following data was provided: architect results = 84.43 and 79.94 miu/ml.Immunochromatography method = negative.Other result = hbsag negative no impact to patient management was reported.
 
Event Description
The customer observed false reactive architect anti-hbs results for one patient.The customer suspects the results to be falsely reactive since it does not match results for the immunochromatography method.The following data was provided: architect results = 84.43 and 79.94 miu/ml immunochromatography method = negative other result = hbsag negative no impact to patient management was reported.
 
Manufacturer Narrative
The complaint investigation included a search for similar complaints, trending data review, labeling review, device history records review, field data, and scientific literature.Return testing was not completed as returns were not available.Review of all the information provided by the customer was reviewed.Ticket trending review did not identify any trends regarding commonalities for complaint lot.Device history review did not identify any non-conformances or deviations with the complaint lot.Historical performance in the field of reagent lots using worldwide data was evaluated.The patient median result for the lot is comparable with all other lots in the field and within established baselines, confirming no systemic issue for the product lot.Labeling was reviewed and sufficiently addresses the customer¿s issue.Additionally, a literature article, ¿interferences in immunoassay¿, tate and ward (2004), clin biochem rev, vol 25, 105, indicates analytical interference can lead to falsely elevated results and according to the literature, there is no single procedure that can rule out all interferences.It is important to recognize the potential for interference in immunoassay and to put procedures in place to identify them wherever possible.Most important is a consideration of the final clinical picture.If there is any clinical suspicion of discordance between the clinical and the laboratory data an attempt should be made to reconcile the difference.The detection of interference may require the use of an alternate assay, or measurement before and after treatment with additional blocking reagent or following dilution of the sample in non-immune serum.Based on the investigation, no systemic issue or deficiency of the architect anti-hbs reagent lot 49197fn00 was identified.All available patient information was included.Additional patient details are not available.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ARCHITECT ANTI-HBS REAGENT KIT
Type of Device
TEST, HEPATITIS B (B CORE, BE ANTIGEN, BE ANTIBODY, B CORE IGM)
Manufacturer (Section D)
ABBOTT IRELAND DIAGNOSTICS DIVISION
finisklin business park
sligo F91VY 44
EI  F91VY44
Manufacturer (Section G)
ABBOTT IRELAND DIAGNOSTICS DIVISION
finisklin business park
sligo F91VY 44
EI   F91VY44
Manufacturer Contact
nicole jenne
max-planck-ring 2
post market surveillance
wiesbaden 65205
GM   65205
6122582960
MDR Report Key18477733
MDR Text Key332728358
Report Number3008344661-2024-00006
Device Sequence Number1
Product Code LOM
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
P050051
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional
Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date 01/24/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received01/09/2024
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue Number07C18-29
Device Lot Number49197FN00
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received01/24/2024
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured02/23/2023
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
ARC I1000SR MOD, 01L86-01, I1SR60811; ARC I1000SR MOD, 01L86-01, I1SR60811
-
-